Literature DB >> 21073069

Prevalence of non-alcoholic fatty liver in a hypercholesterolemic population of northwestern peninsular Malaysia.

Enrico Magosso1, Mukhtar Alam Ansari, Yogheswaran Gopalan, Mohamed Rizal Abu Bakar, Nurzalina Abdul Karim Khan, Jia Woei Wong, Bee Hong Ng, Kah Hay Yuen, Ibrahim Lutfi Shuaib, Kalanithi Nesaretnam.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and a frequent finding on ultrasound examination. NAFLD is considered as the liver component of metabolic syndrome and is linked to accelerated atherosclerosis and cardiovascular disease. No data from systematic studies regarding the prevalence of NAFLD are available for the Malaysian population. One hundred eighty untreated hypercholesterolemic volunteers underwent blood and ultrasound examinations to evaluate their livers. NAFLD was diagnosed in 102 subjects (56.7%) with similar prevalences between sexes. Of the 102 positive subjects 82 (80.4%) were graded as mild, 17 (16.7%) as moderate and 3 (2.9%) as severe fatty liver cases. Elevated fasting plasma glucose (FPG) levels were found in 13 of 180 subjects (7.2%), while elevated AST and ALT levels were seen in 30 (16.7%) and 22 (12.2%) of the180 subjects, respectively.

Entities:  

Mesh:

Year:  2010        PMID: 21073069

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  5 in total

Review 1.  Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations.

Authors:  Robert J Wong; Aijaz Ahmed
Journal:  World J Hepatol       Date:  2014-05-27

Review 2.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

3.  Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial.

Authors:  Enrico Magosso; Mukhtar Alam Ansari; Yogheswaran Gopalan; Ibrahim Lutfi Shuaib; Jia-Woei Wong; Nurzalina Abdul Karim Khan; Mohamed Rizal Abu Bakar; Bee-Hong Ng; Kah-Hay Yuen
Journal:  Nutr J       Date:  2013-12-27       Impact factor: 3.271

4.  Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease.

Authors:  Sumitro Kosasih; Wong Zhi Qin; Rafiz Abdul Rani; Nazefah Abd Hamid; Ngiu Chai Soon; Shamsul Azhar Shah; Yazmin Yaakob; Raja Affendi Raja Ali
Journal:  Int J Hepatol       Date:  2018-09-27

5.  Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association?

Authors:  Hayatul Najaa Miptah; Anis Safura Ramli; Mariam Mohamad; Hilwati Hashim; Zahirah Tharek
Journal:  BMC Fam Pract       Date:  2020-11-20       Impact factor: 2.497

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.